Genetics
Home › Medical research › Multiple sclerosis spasticity
Substantial evidence

Multiple sclerosis spasticity & cannabis

Substantial evidence supports oral cannabinoids for patient-reported MS spasticity. Trials of nabiximols, a THC:CBD spray, show benefit for some patients whose spasticity persists despite other treatment. Some trials first selected people who had already responded, so their results do not establish a general response rate for everyone with MS.

Sources: NASEM 2017 · Nabiximols randomized trial (Novotna 2011)

Most-studied cannabinoids

THCCBD

Safety & cautions

Response is partial and not universal; CNS side effects.

Clinical research below concerns cannabis or cannabinoids, not evidence that a named cultivar treats a condition.

Help us build this responsibly

This page reflects the cited published clinical evidence, and it is a work in progress. Areto is committed to expanding and refining it as new research emerges — so it can genuinely help medical patients make informed choices. If you are a clinician, researcher, or patient with peer-reviewed sources to add, email us at genetics@areto.tech.

Areto Genetics is an educational cannabis catalog. Nothing here is medical advice, and no strain is proven to treat, cure, or prevent any disease. Cannabis affects people differently and carries real risks. Talk to a qualified healthcare provider before using cannabis for any condition — especially if you are pregnant or breastfeeding, an adolescent, taking other medications, or have a heart, liver, or psychiatric condition.